Equity Overview
Price & Market Data
Price: $10.20
Daily Change: -$0.26 / 2.55%
Daily Range: $9.82 - $10.90
Market Cap: $858,811,456
Daily Volume: 1,108,536
Performance Metrics
1 Week: -6.18%
1 Month: 11.02%
3 Months: 32.84%
6 Months: -16.57%
1 Year: -20.11%
YTD: -7.06%
Company Details
Employees: 118
Sector: Health technology
Industry: Biotechnology
Country:
Details
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.